Table 1. Group characteristics.
| Group 1 (bevacizumab to ranibizumab) | Group 2 (ranibizumab to bevacizumab) | P-value | |
|---|---|---|---|
| Number of subjects | 114 | 24 | |
| Women | 77 (68%) | 17 (71%) | 0.753 |
| Age (years) | 77.8±8.2 | 77.5±7.5 | 0.675 |
| Visual acuity, time of switch (logMAR) | 0.52±0.3 | 0.41±0.3 | 0.049 |
| Macular thickness, time of switch (μm) | 418±166 | 340±131 | 0.037 |
| Number of injections before switch | 9.8±4.6 | 8.9±4.0 | 0.316 |
| Better eye treated | 53 (46%) | 9 (38%) | 0.421 |